Halobetasol Propionate

Summary

Halobetasol Propionate (CHEMBL1200908) is an approved small molecule (ATC D07AC21); indicated across 4 conditions including psoriasis and skin disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D07AC21
• Indications: 4 conditions
• Clinical trials: 18
• Chemistry: 485 Da · C25H31ClF2O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200908
Name	Halobetasol Propionate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6918178
ATC	D07AC21
Molecular formula	C25H31ClF2O5
Molecular weight	485
InChIKey	BDSYKGHYMJNPAB-LICBFIPMSA-N

SMILES: CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)CCl

IUPAC name: [(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate

Also known as: BMY-30056, Bryhali, CGP-14,458, CGP-14458, Halobetasol, Halobetasol propionate, IDP-122, Jemdel, Lexette, Ulobetasol, Ulobetasol propionate, Ultravate

Patent coverage: 2,523 distinct patent families (10,126 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Androgen receptor, Progesterone receptor, Muscarinic acetylcholine receptor M1, Alpha-1A adrenergic receptor, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PGR	8.52	AC50	3	nM	CHEMBL_ACT_25204524
AR	7.41	AC50	38.6	nM	CHEMBL_ACT_25203591

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psoriasis	4	MONDO:0005083	EFO:0000676
skin disorder	4	MONDO:0005093	EFO:0000701
atopic eczema	2	MONDO:0004980	EFO:0000274

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE4	5
PHASE2	4
PHASE3	3
PHASE1	3
Not specified	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03987763	PHASE4	RECRUITING	A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
NCT03212963	PHASE4	TERMINATED	Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%
NCT03992261	PHASE4	COMPLETED	Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
NCT04571151	PHASE4	UNKNOWN	Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis
NCT06042647	PHASE4	COMPLETED	Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis
NCT00715975	PHASE2/PHASE3	COMPLETED	Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis
NCT02514577	PHASE3	COMPLETED	Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
NCT02515097	PHASE3	COMPLETED	Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
NCT05608499	PHASE3	TERMINATED	Duobrii Treatment of Acne Keloidalis Nuchae (AKN)
NCT02785172	PHASE2	COMPLETED	Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis
NCT02785185	PHASE2	COMPLETED	Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis
NCT03245385	PHASE2	TERMINATED	Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis
NCT03298581	PHASE2	WITHDRAWN	Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis
NCT00865605	PHASE1	COMPLETED	Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects
NCT01404338	PHASE1	COMPLETED	Assessment for Tachyphylaxis to Topical Corticosteroids in the Treatment of Psoriasis
NCT03058744	PHASE1	COMPLETED	Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis
NCT00802958	Not specified	COMPLETED	Randomized Study to Compare the Bioavailability of Two Halobetasol Propionate 0.05% Topical Ointments
NCT00803166	Not specified	COMPLETED	Randomized Study to Compare the Bioavailability of Three Halobetasol Propionate 0.05% Topical Creams

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).